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Introduction: Our efforts to prevent and treat breast cancer are significantly impeded by a lack of knowledge of
the biology and developmental genetics of the normal mammary gland. In order to provide the specimens that
will facilitate such an understanding, The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center
(KTB) was established. The KTB is, to our knowledge, the only biorepository in the world prospectively established
to collect normal, healthy breast tissue from volunteer donors. As a first initiative toward a molecular understanding
of the biology and developmental genetics of the normal mammary gland, the effect of the menstrual cycle and
hormonal contraceptives on DNA expression in the normal breast epithelium was examined.
Methods: Using normal breast tissue from 20 premenopausal donors to KTB, the changes in the mRNA of the
normal breast epithelium as a function of phase of the menstrual cycle and hormonal contraception were assayed
using next-generation whole transcriptome sequencing (RNA-Seq).
Results: In total, 255 genes representing 1.4% of all genes were deemed to have statistically significant differential
expression between the two phases of the menstrual cycle. The overwhelming majority (221; 87%) of the genes
have higher expression during the luteal phase. These data provide important insights into the processes occurring
during each phase of the menstrual cycle. There was only a single gene significantly differentially expressed when
comparing the epithelium of women using hormonal contraception to those in the luteal phase.
Conclusions: We have taken advantage of a unique research resource, the KTB, to complete the first-ever
next-generation transcriptome sequencing of the epithelial compartment of 20 normal human breast specimens.
This work has produced a comprehensive catalog of the differences in the expression of protein-coding genes as a
function of the phase of the menstrual cycle. These data constitute the beginning of a reference data set of the
normal mammary gland, which can be consulted for comparison with data developed from malignant specimens,
or to mine the effects of the hormonal flux that occurs during the menstrual cycle.* Correspondence: susan.clare@northwestern.edu
†Equal contributors
1Department of Surgery, Feinberg School of Medicine, Northwestern
University, 303 East Superior Street, Chicago, IL 60611, USA
Full list of author information is available at the end of the article
© 2014 Pardo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Pardo et al. Breast Cancer Research 2014, 16:R26 Page 2 of 16
http://breast-cancer-research.com/content/16/2/R26Introduction
In 1997, the National Cancer Institute (NCI) convened
a meeting of researchers from academia, industry and
government, and representatives of the patient advo-
cate community. The purpose of the meeting was to
identify deficiencies that would have to be addressed if
we are to continue and accelerate progress in treating
breast cancer, and ultimately, to prevent this disease.
Thirteen deficiencies were identified, the first of which
was as follows:
‘Our limited understanding of the biology and
developmental genetics of the normal mammary gland
is a barrier to progress. …it is now clear that a more
complete understanding of the normal mammary
gland at each stage of development—from infancy
through adulthood—will be a critical underpinning of
continued advances in detecting, preventing, and
treating breast cancer [1]’.
The ideal approach to end the scourge of breast cancer
would be to prevent it. Annual age-adjusted breast can-
cer incidence rates in the United States are a testament
to the lack of effective prevention strategies [2]. Current
breast cancer prevention strategies fall into one of three
categories: lifestyle modification, surgical intervention,
and chemoprevention. Lifestyle modifications are di-
rected at women with the general population risk of
breast cancer, and modifications include limiting post-
menopausal weight gain and moderation of alcohol in-
take. Surgical intervention, by convention, has been
limited to those women estimated to be at substantially
increased risk of breast cancer, including women with
known or suspected germline mutations in BRCA1 or
BRCA2, or a family history of breast and/or ovarian
cancer among first- and second-degree relatives. Surgical
interventions include bilateral prophylactic mastectomy,
bilateral salpingo-oophorectomy or a combination of
both procedures. Multiple chemoprevention trials exam-
ining the efficacy of tamoxifen (for example, NSABP-P1,
IBIS-1), raloxifene (MORE, CORE, STAR) and aromatase
inhibitors have been completed [3-9]. All chemopreventa-
tive agents identified to date, with a single exception, were
introduced into the clinic as breast cancer treatments; a
significant reduction in the rate of contralateral breast
cancer in treated patients was used as an indication
that these treatments also act to prevent breast cancer.
Few, if any, interventions are based on an understand-
ing of breast cancer risk or of how risk is transduced at
the molecular level.
The Susan G. Komen for the Cure Tissue Bank at the
Indiana University (IU) Simon Cancer Center (KTB, The
Bank) was established expressly as a resource to be used
to address the deficiency identified by the NCI’s ProgressReview Group and stated above [10]. To the best of our
knowledge, the KTB has the largest and most varied
collection of normal breast tissue in the world. The
KTB was organized as a clinical trial, and specimens
are obtained under broad consent. Healthy volunteer
women are recruited by flyer, workplace newsletter, and
email solicitation by friends and acquaintances. Donors
present to a clinic on a weekend day. They fill out a
questionnaire, which provides detailed information on
their menstrual history, reproductive history, personal
health history, medication usage and family history of
breast, ovarian and other cancers. Blood is obtained
and processed for leukocyte DNA, as well as for serum
and plasma. Breast tissue acquisition is done utilizing
a 10-gauge breast biopsy system. Three tissue cores are
fresh frozen in liquid nitrogen within five minutes of ex-
traction and a fourth is fixed in formalin and paraffin-
embedded (FFPE).
As a first initiative toward a molecular understanding
of the biology and developmental genetics of the nor-
mal mammary gland, the effect of the menstrual cycle
and hormonal contraception on DNA expression in the
normal breast epithelium was examined. The normal
epithelium was chosen for sequencing for two major
purposes: 1) to determine how DNA expression changes
as a consequence of the menstrual cycle in the func-
tional unit of the breast, that is, the ductal/lobular
epithelium; and 2) anticipating that this sequencing in-
formation would be used as a normal control in breast
cancer experiments, the epithelium was deemed to be
the best comparator as it is hypothesized that breast
cancer originates in the terminal ductal lobular unit of
the epithelium. This manuscript reports the findings for
protein-coding genes.
The human mammary gland undergoes rounds of pro-
liferation, differentiation, and regression/involution in
response to cyclic fluctuations in the concentration of
ovarian steroidal hormones. Much of what is known
about the specific changes in the normal mammary
gland as a function of these hormones comes from the
study of other mammals [11,12]. A large proportion of
our knowledge of menstrual cycle effects in the human
breast comes from histologic observations [13], and
studies of markers of proliferation and apoptosis. It is
known that the mitotic index is low during the follicu-
lar phase with the peak of mitotic activity occurring in
the mid to late luteal phase [14,15]. In the event that a
pregnancy does not occur, to prevent hyperplasia fol-
lowing the cell proliferation of the luteal phase, apop-
tosis must be activated to clear the superfluous cells.
There is evidence to suggest that apoptosis occurs du-
ring the luteal phase [16], while other researchers have
found no differences between the phases [17]. With the
identification of the breast stem cell, attention has
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and its niche. Asselin-Labat and colleagues demon-
strated markedly decreased murine mammary stem cell
numbers and outgrowth potential as a consequence of
the elimination of steroidal hormones following ovari-
ectomy [18]. Joshi et al. observed that the number of
mouse ‘mammary stem cell-enriched basal cells’ in-
creases at diestrus or following the administration of
exogenous progesterone [19]. Breast malignancies also
appear to be affected. Murine breast cancers fluctuate
in size as a function of the menstrual cycle, thought
likely a consequence of the periodic proliferation and
apoptosis driven by the hormone flux [20]. Human tu-
mors show increased proliferative activity as a function
of the menstrual cycle [21], but measures of apoptosis
remain unchanged [22].
Materials and methods
All studies were approved by the Indiana University In-
stitutional Review Board (IRB-04, protocol number
0709–17; IRB-01, protocol number 1110007030). All re-
search was carried out in compliance with the Helsinki
Declaration. Donors provide broad consent for the use
of their specimens in research. The consent document
informs the donor that the donated specimens and med-
ical data will be used ‘for the general purpose of helping
to determine how breast cancer develops’. It is explained
in the consent that the exact laboratory experiments are
unknown at the time of donation, and that proposals for
use of the specimens will be reviewed and approved by a
panel of ‘independent researchers’ before specimens
and/or data are released for research purposes.
Premenopausal donors to the KTB were identified by
a query of the Bank’s database. Hematoxylin and eosin-
stained sections of the FFPE tissue of the identified do-
nors were reviewed and tissue was graded on the basis
of the abundance of epithelium within the section. Only
cores containing abundant epithelium were considered
for this study. Based on dates, the specimens of nine
women in the follicular phase of the menstrual cycle and
five in the luteal phase were chosen (Table 1). Six donors
using hormonal contraception at the time of donation
were also included (Table 1). Whole blood obtained from
19 of the 20 donors at the time of tissue donation was
processed for serum. Estradiol, estriol, luteinizing hormone
(LH) and progesterone concentrations were determined
by the IU Health Pathology Laboratory using a Beckman
Unicel DxI 800 Immunoassay System (Beckman Coulter,
Brea, CA, USA). The phase of the menstrual cycle was
verified by serum progesterone concentration (Table 1).
The epithelium of these 20 specimens was microdissected
from multiple 8 micron thick frozen tissue sections. Total
RNA extracted from the tissue was subsequently depleted
of rRNA via locked nucleic acid probes (see Additionalfile 1). This enabled profiling of both poly-A and non-
poly-A RNA species. Barcoded cDNA libraries from the 20
normal breast epithelia were prepared and sequenced on
an Applied Biosystems (AB) SOLiD 3 or SOLiD 4 platform
(Life Technologies, Foster City, CA, USA) (Table S1 in
Additional file 2). Whole transcriptome sequencing (RNA-
Seq) reads for each sample were then mapped to the
human genome (hg19) using the LifeScope software ver-
sion 2.5.1 (Life Technologies) and Binary Alignment/Map
(BAM) files were generated. The files can be accessed
using the Database of Genotypes and Phenotypes (dbGaP)
[23,24], study accession number phs000644.v1.p1. Read
counts for each gene were derived from the output BAM
files using the RefSeq database (UCSC Genome Brower)
as the gene model. The total number of reads and the
mapped reads are provided in Table S2 in Additional file 2;
the raw read counts of the individual genes are listed in
Table S3 in Additional file 2.
The original data comprised 25,203 sequenced genes,
many of which exhibit very low expression levels. Omit-
ting low-expression genes that contribute little to the
analysis yields a more powerful statistical test overall,
that is, the asymptotic theory required by the statistical
tests is satisfied. Genes that had average counts greater
than 5 across all samples were retained for analysis. A
total of 7,208 genes were removed based upon this cri-
terion (28.6% of the original number); 17,995 genes
remained for analysis.
Statistical analysis
Differential expression (DE) was tested using the Biocon-
ductor package edgeR in R (v. 2.15). A negative binomial
(NB) distribution was employed to model the count data
generated from the RNA-Seq experiments.
Three similar general linear models were employed to
test a set of three hypotheses. In addition to modeling
the effects of membership in the groups of interest (lu-
teal phase, follicular phase, and contraceptives), terms
are also included to model the effects of batch member-
ship. Specifically, Batch 1 (samples 1 through 10) acts as
the baseline for comparison, and the coefficients for
Batch 2 (samples 11 through 20 except 19) and Batch 3
(sample 19) indicate departures from that baseline.
These terms ensure that the systematic differences in ex-
pression that are present between batches, including dif-
ferences due to single-end versus paired-end reads, are
not falsely attributed to differential expression between
the actual groups of interest. Details are provided in
Additional file 1.
There are situations when a set of genes is highly
expressed in one sample but not in another. When this
occurs, the remainder of the genes in the first sample
would be ‘under-sampled’, and thus creates a potential
bias due to its particular RNA composition. To prevent
Table 1 Age, menstrual phase data and hormonal contraception (HC) formulation
Sequencing ID Age Menstrual day HC HC type F or L Estradiol pg/mL Progesterone ng/mL LH milliunits/mL
Normal_1 37 5 no F 49 0.5 5.7
Normal_2 20 14 yes Tri-Legest Fe - 32 1.5 9.6
Normal_3 30 13 no F 32 <0.01 3.6
Normal_4 44 19 yes Ortho Tri-Cyclen Lo - 432 0.4 5.1
Normal_5 40 9 no F 28 0.5 5.6
Normal_6 27 27 yes Nuvaring - N/A N/A N/A
Normal_7 23 29 no L 71 6.1 3.2
Normal_8 27 25 no L 82 3.7 4.9
Normal_9 39 4 no F 198 0.1 N/A
Normal_10 38 26 no L 131 21.4 3
Normal_11 22 28 yes Necon1-35 - 36 1.1 0.2
Normal_12 45 27 no L 47 2.9 3.6
Normal_13 19 7 yes Zenchent - 26 0.7 2.4
Normal_14 36 2 no F 53 0.6 4.4
Normal_15 26 9 no F 43 0.9 10.3
Normal_16 22 29 no L 136 12.4 5.3
Normal_17 46 6 no F 121 0.5 5.6
Normal_18 31 29 yes LoEstrin 24 - 34 1.1 2
Normal_19 29 2 no F 61 0.6 7.9
Normal_20 21 7 no F 43 0.3 3.5
HC type
Tri-Legest Fe 1 mg norethindrone acetate and 20 mcg ethinyl estradiol × 1 week; 1 mg norethindrone acetate and 30 mcg ethinyl estradiol ×
1 week; 1 mg norethindrone acetate and 35 mcg ethinyl estradiol × 1 week
Ortho Tri-Cyclen
Lo
0.180 mg of norgestimate and 0.025 mg ethinyl estradiol × 1 week; 0.215 mg of norgestimate and 0.025 mg ethinyl estradiol ×
1 week; 0.250 mg of norgestimate and 0.025 mg of ethinyl estradiol × 1 week
Nuvaring
Necon1-35 Norethindrone 1 mg, ethinyl estradiol 35 mcg
Zenchent 0.4 mg norethindrone and 0.035 mg ethinyl estradiol
LoEstrin 24 1 mg norethindrone acetate and 20 mcg ethinyl estradiol
Menstrual day was calculated from information provided by the donor on her questionnaire and verified by serum progesterone concentration. F, follicular; L,
luteal; LH, luteinizing hormone.
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results, the data was normalized using an empirical
approach that estimates bias [23]. The scaling factors
that were estimated ranged from 0.4402 to 1.3760 across
the 20 samples; the departure of these factors from 1 indi-
cates the presence of compositional differences between
libraries.
The NB model includes ψg as a dispersion parameter.
Initially a common dispersion was estimated, which is
the average ψg across all genes, and then this was ex-
tended by estimating a separate dispersion for each indi-
vidual gene. This was done using an empirical Bayes
method that ‘squeezes’ the gene-wise dispersions toward
the common dispersion, thus allowing for information
borrowing from other genes [25].Adjustments for multiple testing
Since a separate statistical test is performed for all of the
17,995 genes, it is necessary to adjust the P values for
multiple testing (to control the Type I error rates across
the ‘family’ of genes rather than for ‘each’ gene). This
was accomplished using the Benjamini-Hochberg pro-
cedure for controlling the expected proportion of incor-
rectly rejected null hypotheses, also known as the false
discovery rate (FDR) [25].
Residual RNA from specimens 11 to 20 was utilized to
validate the sequencing findings. TaqMan qPCR was per-
formed for 29 genes (Additional file 1). qPCR reactions
were run on an ABI 7900HT Real-Time PCR System
and data analyzed using the SDS2.3 and DataAssist v2.0
software from Applied Biosystems.
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Networks and functional analyses were generated through
the use of Ingenuity Pathway Analysis (IPA) (Ingenuity
systems, [26]) and the database for annotation, visuali-
zation and integrated discovery (DAVID) [27,28] bioinfor-
matics resources.
Ki-67 immunohistochemistry
Tissue cores were placed in 10% neutral buffered for-
malin within 5 minutes of acquisition and delivered to
IU Health Pathology for routine paraffin embedding.
Sections 3 to 5 microns thick were deparaffinized and
hydrated to running water. Antigen retrieval was car-
ried out in the pretreatment module (DAKO, Carpinteria,
CA, USA) using low pH target retrieval (DAKO). All
staining was performed on the AutoStainer Plus (DAKO).
Sections were incubated with 3% H2O2 for 5 minutes
and subsequently exposed to the primary antibody,
Ki-67 (Mib-1, DAKO), for 20 minutes. Horseradish
peroxidase-labeled secondary antibody (EnVision™/HRP)
was placed on the tissue for 20 minutes followed by
3,3′-diaminobenzidine (DAB) + chromogen for 10 mi-
nutes. Sections were counterstained with EnVision™ Flex
Hematoxylin (DAKO). The pathologist (SB) was blinded
as to the phase of the menstrual cycle or to the use of
hormonal contraception (HC). Each section was classi-
fied from grade 1 to 4 where 1 is the lowest number of
cells stained/slide and 4 is highest number of cells
stained/slide.
Results
Gene expression differences between the follicular and
luteal phases of the menstrual cycle.
Some 255 genes representing 1.4% of all genes were
deemed to have statistically significant differential expres-
sion between the two phases of the menstrual cycle (Table
S4 in Additional file 2). A total of 221 of the genes have
higher expression during the luteal phase.
The genes with significant differential expression were
analyzed using IPA. The molecular and cellular func-
tions enriched in the gene list are provided in Table 2.
These functions occur during the luteal phase. The top
three networks as determined by IPA were merged and
are presented in Figure 1. A total of 151 of the 255 genes
are periodically expressed in the cell cycle as determined
by comparison to lists generated in HeLa cells [29],Table 2 Biologic functions in the luteal phase
Function P value
Cell cycle 1.36E-28-1.22E-02
Cellular organization and assembly 1.36E-28-1.22E-02
DNA replication, recombination and repair 1.36E-28-1.22E-02
Top biologic functions of differentially expressed genes as determined by
Ingenuity Pathway Analysis.foreskin fibroblasts [30], immortalized keratinocytes [31]
and osteosarcoma [32] cell lines. Genes are displayed by
the cell cycle phase in which they are expressed as well
as by Gene Ontology (GO) biologic process terms in
Table 3. GO biologic processes were ranked by statistical
significance by DAVID; the top 30 are listed in Table S5
in Additional file 2.
A closer look at several of these genes and the processes
they are involved in as well as non-cell cycle-controlled
genes follows.
Luteal phase genes
Two of the major cellular events occurring during the cell
cycle are DNA replication and mitosis. These events must
occur at a specific time within the cycle and be successfully
completed before progression to the next phase. Transcrip-
tion of the genes that control or execute these functions is
initiated by transcription factors. Both E2F1 and FOXM1
have higher expression during the luteal phase. Upstream
analysis by IPA (Table S6 in Additional file 2) predicts
E2F1 and MYC, and FOXM1 (Table S7 in Additional file
2) are activating gene transcription during the luteal phase
while NUPR1 is the most significantly inhibited releasing
its suppression of transcription (Figure 2).
DNA replication
Initiation of DNA replication at the replication origins
There are four phases that occur during the initiation of
DNA synthesis: recognition of the replication origins, as-
sembly of the pre-replication complexes (pre-RC), activa-
tion of the DNA helicase(s) and loading of the replicative
enzymes [33]. DNA becomes licensed for replication dur-
ing late mitosis or the early G1 phase by the formation of
pre-RC on replication origins [34]. Origins of replication
are bound by origin replication complex (ORC)1-6 pro-
teins and these form the platform for the loading of the
minichromosome maintenance (MCM) proteins by CDC6
and CDT 1 to form the pre-RC. The expression of ORC1,
ORC6, CDC6, CDT1, MCM2, and MCM4 are increased
during the luteal phase in the normal breast epithelium.
The CMG complex consisting of the CDC45, MCM2-7
and the GINS proteins functions as a helicase. The expres-
sion of CDC45, MCM2 and 4 and GINS1 and 2 was ob-
served to be increased during the luteal phase. With
regard to the final step, the replicative enzymes, PCNA
and POLE were increased in the luteal phase.
DNA damage
BRCA1, RAD51, RAD54L, CHEK1, XRCC2, HJURP, RMI2
and BLM are involved in homologous recombination [35],
and the expression of all seven genes increases during the
luteal phase. BRIP1, which interacts with the BRCT repeats
of BRCA1 and is important to BRCA1 function, is also in-
creased [36]. HMMR and MAD1L1 are both more highly
Figure 1 Ingenuity Pathway Analysis networks. The three most significant networks as determined by Ingenuity Pathway Analysis were
merged. The top functions represented in this figure are cell cycle; cellular assembly and organization; DNA replication, recombination, and repair.
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these genes associate in protein complexes with BRCA 1
and BRCA2 [37]. Base excision repair (BER) is represented
by NEIL3 [38], POLE2, UNG and PCNA. Fanconi anemia
proteins are required for the repair of DNA cross-links
[39]; FANCA expression is higher in the luteal phase.
EXO1, the protein product of which is involved in DNA
end resection and double-strand break repair, is increased
during the luteal phase. DNA polymerase POLQ is more
highly expressed during the luteal phase. This polymerasehas the unique ability to bypass blocking lesions such as
abasic sites and thymine glycols [38]. It is also able to ex-
tend unpaired termini [38].
Mitosis
The terms associated with the gene group with the high-
est enrichment score as determined by the gene func-
tional classification tool in DAVID are M phase and
mitosis. Forty-seven (21%) of the 221 genes with in-
creased levels of expression during the luteal phase are
Table 3 Cell cycle phase and function
G1/S S G2 G2/M M/G1
DNA replication initiation CDC45L MCM10
CDC6
MCM2
MCM4
ORC1
ORC6
CDT1
Nucleotide metabolism DTYMK
RRM2
DNA replication and repair BRIP1 TYMS TOP2A FANCA
BLM RAD54L
DNA2 NEIL3
RAD51 PTTG1
EXO1 POLQ
POLE2 TRIP13
PCNA KIAA0101
UNG
BRCA1
GINS2
DTL
Chromatin assembly and disassembly HELLS HIST1H1B HJURP ASF1B
EZH2 HIST1H1D
HIST1H2AB
HIST1H2AH, HIST1H2AK, HIST1H2AM, HIST1H2AG,
HIST1H2AL
HIST1H2AJ
HIST1H2BH
HIST1H2BF, HIST1H2BE
HIST1H2BL
HIST1H2BM
HIST1H2BN
HIST1H2BO
HIST1H2AD, HIST1H3C, HIST1H3F, HIST1H3G, HIST1H3B,
HIST1H3H, HIST1H3J, HIST1H3A, HIST1H3D
HIST1H4L, HIST1H4F, HIST1H4A
Cell cycle regulation-interphase CLSPN CCNA2
E2F1 CKS2
CHEK1 MKI67
Cell cycle regulation-mitosis FBXO5 FOXM1 CCNB1
CCNB2
CDC20
CDC25C
CIT
MELK
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Table 3 Cell cycle phase and function (Continued)
PKMYT1
UBE2C
Microtubules and spindle formation KIF11 KIF18A
KIF14 KIF4A
KIF15
KIF23
KIF2C
SPAG5
TPX2
Spindle regulation BUB1B ASPM
BUB1
AURKB
PLK4
PRC1
TTK
Chromosome segregation NDC80 ZWINT NUF2 BIRC5 ESPL1
SPC25 NCAPG CENPE CENPF
DSCC1 NCAPH DLGAP5
SGOL1 KIFC1
CASC5 NUSAP1
Cytoskeleton AMPH CKAP2L
Nuclear membrane LAMB1
Transcription ATAD2 MLF1IP
CDCA7
ZNF367
Nuclear division CDCA2 ANLN
FAM83D CDC20
CDCA3
GTPase activator activity DEPDC1
DEPDC1B
ARHGAP-11A
IQGAP3
Cytokinesis PBK RACGAP-1
ECT2
KPNA2
Membrane transport ABCC2
Metabolic process HMMR CBR3
HSPH1 ELOVL6
SRD5A1
Differentially expressed genes were allocated to a phase of the cell cycle by referring to phase allocations for HeLa cells [29], foreskin fibroblasts [30],
immortalized keratinocytes [31] and osteosarcoma cells [32]. Functions were assigned by referring to Bar-Joseph et al. [30], the database for annotation,
visualization and integrated discovery (DAVID) and Ingenuity Pathway Analysis (IPA). Table modeled after Table S3 in Additional file 2 in reference [30].
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mitosis and increased in expression during the luteal
phase is provided in Table S8 in Additional file 2. Whilenot intended to be exhaustive, a survey of some of the
functions during mitosis of the encoded gene are also
provided in the table. Recent studies employing small
Figure 2 Transcription factor targets. Ingenuity Pathway Analysis upstream analysis was employed to determine the transcription factor (TF)
pathways activated and inhibited during the luteal phase. This figure displays the E2F1, MYC, FOXM1 And NUPR1 targets whose expression
changes during the luteal phase. Genes with increased expression in the luteal phase are indicted in red, those decreased in green. Orange TFs
are activated and blue are inhibited. Line color indicates the following: orange: activation, blue: inhibition, yellow: findings inconsistent with the
state of the downstream molecule, and grey: an effect not predicted.
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enabled the kinetochore proteins to be assigned to com-
plexes with specific functions at the kinetochore [33-35].
Using this information it was possible to assign three
genes increased during the luteal phase to the Ndc80
complex, two to the chromosome passenger complex
(CPC), three to the constitutive centromere-associated
network (CCAN) and three to the spindle assembly
checkpoint (SAC). Nine kinesin motor protein genes
also demonstrate increased expression.Paracrine signaling
RANKL, WNT4 and EREG are all overrepresented dur-
ing the luteal phase.
Hormones
GHR expression is increased during the luteal phase as
are PTHLH and SRD5A1. SRD5A1 catalyzes the conver-
sion of progesterone to the 5alpha-pregnanes, which are
mitogens in the normal human breast [40]. It also con-
verts testosterone to dihydroxytestosterone, which has
Table 4 Validation cohort
Gene logFC
(RNA-Seq)
P value Fold change
(qPCR biological
validation)
Validation
status
AURKB 1.694476904 1.10E-05 8.56 V
BRCA1 1.042815222 4.95E-06 2.39 V
BUB1 1.526455024 2.82E-07 2.95 V
BUB1B 1.602146974 8.86E-07 3.87 V
CCNB1 1.055253675 9.55E-05 2.73 V
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PTHLH promotes nipple formation and mammary duct
branching during embryogenesis and has an important
role in calcium transport in the lactating gland [42].
ESRRB encodes the estrogen-related receptor beta, an
orphan nuclear receptor. This protein would seem to
have disparate functions in that it is a key regulator of
embryonic stem cell self-renewal in the mouse [43,44],
however, its ortholog functions as a metabolic switch
during development in the Drosophila [45].CDC25C 2.501848634 4.13E-11 6.1 V
CDC6 1.49654134 2.33E-08 3.76 V
CDK1 1.965582801 6.77E-12 6.33 V
CENPE 1.462857192 1.39E-06 3.05 V
CLSPN 1.383625655 6.57E-06 6.07 VMatrix metalloproteinases
MMP3 and ADAMTS9 are both higher in expression
during the luteal phase. MMP3 plays a role in mammary
gland branching morphogenesis [46,47].E2F1 0.996887203 0.000372 3.06 V
ECT2 0.872573718 0.000152 1.89 V
ERCC6L 1.102811499 8.88E-05 0.79 N
FANCA 1.224811173 1.63E-06 4.33 V
FOXM1 1.92032584 2.17E-07 8.43 V
HIST1H2AH 1.485622497 0.000196 0.99 N
HIST1H2AJ 2.284502132 8.84E-06 2.96 V
HIST1H2AM 1.530373984 0.000151 1.98 V
HIST1H2BH 1.563333889 3.04E-07 1.32 V
HIST1H3B 2.979880506 6.94E-16 1.43 V
KIF20A 1.876073752 5.20E-08 8.09 V
KIF23 1.604227334 1.98E-09 3.22 V
NCAPG 1.888216879 2.37E-10 7.2 V
PCNA 0.939041116 1.44E-05 2.09 V
RAD51 1.255859843 1.79E-05 4.75 V
RRM2 2.285244825 5.90E-09 1.3 V
TK1 1.410412144 2.83E-05 5.67 VFollicular phase genes
Thirty-four of the 251 differentially expressed genes
show increased expression during the follicular phase.
They can be assigned to categories based on function.
Two are associated with fat droplets in milk: BYN1A1,
MUC15. Three genes encode ion channels or trans-
porters: GLRA3, NHEDC1, and KCNT2. Two genes are
associated with a fully differentiated phenotype: HOXB6,
TFCP2L1. A number of genes encode proteins with
metabolic functions: CYP4Z1, CYP4X1, HMGCS2, and
PCK1. PCK1 expression in the normal mammary gland
results in gluconeogenesis and glycerolneogenesis [48].
PCK1-dependent glyceroneogenesis may contribute to
the formation of milk triglycerides in epithelial cells dur-
ing lactation [49]. PI3 is a serine protease inhibitor that
has antibacterial activity against Gram-positive and
Gram-negative bacteria as well as fungal pathogens on
epithelial surfaces [50].TPX2 2.025558609 1.21E-10 5.49 V
TYMS 1.667388087 2.36E-09 5.64 V
TaqMan qPCR was performed for 29 genes representing the DNA replication
and mitosis clusters. Twenty-seven of 29 were validated. RNA-Seq, whole
transcriptome sequencing; V, validated; N, not validated.Effect of hormonal contraception
CCDC144A was the only gene differentially expressed
between the hormone contraceptive group and luteal
phase group (Table S9 in Additional file 2). This gene
encodes a protein of unknown function.qPCR validation
Twenty-nine genes were selected for qPCR validation;
the expression of 27 of the 29 was validated (Table 4).Ki-67 immunohistochemistry
Ki-67 immunohistochemistry shows strong (4) staining
in the tissue sections from donors in the luteal phase or
those using HC (Table S10 in Additional file 2). All sec-
tions demonstrating weak staining were from donors in
the follicular phase. Intermediate staining (2 to 3) was
mixed among both phases and donors using HC.Discussion
The functioning ovaries produce relatively large amounts
of estradiol and progesterone in a cyclical pattern ap-
proximately every 28 days. The mid-cycle estrogen peak
concentration can be 10 times that in the early follicular
phase and progesterone serum concentrations are 10-
fold higher in the luteal phase than follicular phase. In
this study, next-generation RNA sequencing has been
utilized to determine how these changes in serum ster-
oid hormone concentrations effect breast epithelial gene
expression. Gene expression in the breast epithelium of
women using HC has also been assayed to determine
the effects of these exogenous hormones. A total of 255
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two phases of the menstrual cycle, of these 221 (87%)
were more highly expressed during the luteal phase.
The specific changes in gene expression observed in
the human breast epithelium as a function of the men-
strual phase confirm and expand upon the results of
Graham et al. who used both breast organoids and cell
lines to test the effects of progesterone treatment [51].
The specific functions identified by those investigators
were DNA replication, the G2/M checkpoint and kineto-
chore function, and the G1/S transition. A large percent-
age of the genes expressed during the luteal phase are
cell cycle regulated and they can be broadly placed into
one of two clusters: DNA replication and mitosis. The
DNA replication cluster includes genes involved in DNA
synthesis, including components of the pre-RC, nucleo-
tide biosynthesis, DNA replication, DNA packaging, S
phase regulation and DNA repair. The G1/S phase tran-
scription phase regulator E2F1 binds to the promoter
and thereby initiates the transcription of most genes in
this cluster [32]. E2F1 transcription, in turn, is stimu-
lated by the increased progesterone concentration dur-
ing the luteal phase. This may be the direct result of the
binding of the E2F1 promoter by the progesterone re-
ceptor (PR) [52]. Progesterone may also act by increas-
ing the expression of MYC [53], which subsequently
facilitates, directly and indirectly, the expression of
E2F1 [54,55]. The mitosis cluster contains genes involved
in the processes of chromosome segregation, spindle
organization, protein-DNA complex assembly, regulation
of mitosis and cytokinesis. The promoters of most of
these genes are bound by FOXM1. FOXM1 has a pivotal
role in the regulation of cell proliferation and cell cycle
progression. It exerts control on the G1/S transition, S-
phase progression, DNA replication, centriole duplica-
tion, sister chromatid cohesion, G2/M transition, mitosis,
DNA damage response and DNA repair [56]. Increased
FOXM1 expression during the luteal phase is likely an in-
direct effect of the change in the concentration of ovar-
ian steroids. Grant et al. state that E2F1 does not bind to
the promoter of FOXM1 [32], however, chromatin im-
munoprecipitation reveals binding of E2F1 to the prox-
imal promoter of FOXM1 in MCF-7 cells [57]. FOXM1
has been shown also to be regulated by TNFSF11
(RANKL) [58] and 14-3-3ζ [59]. Additional data reported
by Bergamaschi, Katzenellenbogen and colleagues is also
of interest: just over one-third of the 29 genes they iden-
tified to be significantly associated with 14-3-3ζ overex-
pression, tamoxifen resistance, FOXM1 expression, and
the luminal B and a minority of basal subtypes of breast
cancer have higher expression in the luteal phase [59].
The level of FOXM1 expression has also been shown to
be correlated with the effectiveness of a number of other
breast cancer therapies including herceptin [60], gefitinib[61], lapatinib [62], paclitaxel [60], and cis-platinum [63].
The downregulation of NUPR1, although not observed at
the transcript level, is inferred by IPA upstream analysis.
NUPR1, also known as p8 and COM1, is a chromatin-
binding protein, which inhibits cell proliferation [64]. Re-
ducing the expression of this protein accelerates the kin-
etics of G1 progression to S phase [64]. Clinical breast
cancer studies have demonstrated significantly decreased
p8 nuclear staining in breast cancer cells [65].
Only a small percentage of normal mammary cells are
estrogen receptor (ER) and/or PR+ and mammary stem
cells lack these receptors. Nevertheless, progesterone elicits
significant changes in gene expression, which must be me-
diated by other factors. Brisken and colleagues have dem-
onstrated that progesterone’s effect on mammary gland
morphogenesis is mediated by WNT4 [66,67] and prolifer-
ation by RANK ligand [68], both acting by a paracrine
mechanism. RANK ligand and WNT4 have been identified
as paracrine effectors of progesterone-induced mammary
stem cell expansion [18,19]. The data presented in this
paper reveals increased expression of these genes during
the luteal phase, likely a consequence of the increased pro-
gesterone concentration during this phase. Amphiregulin
(AREG) has also been shown to be a downstream target of
progesterone in the mouse mammary epithelium and its
actions thought to be paracrine [69]. The expression of
AREG was not increased during the luteal phase, however,
another member of the epidermal growth factor family,
epiregulin (EREG), was increased. EREG is an autocrine
growth factor for normal human keratinocytes [70]. It can
also induce the resumption of meiosis [71].
Asselin-Labat and colleagues utilized fluorescent-
activated cell sorting to divide mouse mammary cells
into luminal (CD29loCD24+) and mammary stem cell-
enriched (CD29hiCD24+) subfractions [18]. They then
compared gene expression in these two subfractions as a
function of ovariectomy. It is interesting to note that 54
(21%) of the genes differentially expressed as a function
of the menstrual cycle are decreased as a consequence of
ovarian hormone deprivation (Table S11 in Additional
file 2). The reprise of these genes in the Asslin-Labat
study is confirmatory evidence that the changes in the
expression of these genes are indeed a consequence of
the elaboration of ovarian hormones.
ESSRB expression was increased during the luteal phase.
In Drosophila the activated single estrogen-related recep-
tor ortholog causes a metabolic switch to a form of aer-
obic glycolysis that is reminiscent of the Warburg effect. It
is tempting to speculate that a metabolic switch, such as
occurs in Drosophila, provides the building blocks for the
synthesis of amino acids, lipid and nucleotides required
for the proliferation taking place during the luteal phase.
Many of the cell cycle genes identified with increased
expression during the luteal phase have been shown to
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tion as to whether they have a role in oncogenesis or if
the increased expression is simply a reflection of prolif-
erating tumor cells. An increased number of ovulatory
menstrual cycles and the prolonged use of progestin-
containing hormone replacement therapy are both asso-
ciated with an increased risk of the development of
breast cancer [72,73]. Pike and colleagues hypothesized
almost two decades ago that many of the epidemiologic
observations regarding the relation of ovarian/steroidal
hormones to breast cancer risk could be explained by an
increased mitotic rate [14]. An increased mitotic rate
may be increased mitotic activity above some baseline
rate or it may be the division of a subset of cells that
would ordinarily not be dividing, that is, stem cells. Joshi
and colleagues clearly demonstrated that progesterone is
driving the proliferation of murine mammary breast
stem cells [19], and stem cells are likely to have accumu-
lated a wealth of DNA lesions during their quiescence.
Pike’s increased mitotic rate is likely a surrogate for cells
re-entering and traversing the cell cycle. There are nu-
merous redundant systems functioning during the cell
cycle to ensure the correct replication of DNA and seg-
regation of chromosomes; and, in those instances where
repair cannot be affected, to eliminate those cells. Never-
theless, some of the products of the genes identified to
have increased expression in the luteal phase genes
have tight tolerances meaning there is a small margin of
error. For example, both depletion and overexpression
of KIAA0101 result in supernumerary centrosomes. The
cell cycle is regulated by transcription, phosphorylation
and ubiquitination events that must occur at a precise
time within the cell cycle. Loss of this temporal control,
such as the inappropriate expression of the progesterone-
driven genes identified in the luteal phase, can result in
genomic instability [74].
Oral contraceptives have been shown to leave the mi-
totic activity in the breast effectively unchanged when
compared to a normal menstrual cycle and therefore have
no chemopreventative effect [75]. These epidemiologic
observations are substantiated by the findings of this se-
quencing study: there was only a single gene significantly
differentially expressed when comparing the breast epithe-
lium of women taking HC to women in the luteal phase of
the menstrual cycle. The breast epithelium of a woman
taking HC experiences a continuous luteal phase during
the weeks that the breasts are exposed to the exogenous
hormones. These hormones drive mitosis, cell cycle pro-
gression and proliferation using the same genetic pro-
grams as with endogenous ovarian hormones.
Conclusions
Fundamental insights into the prevention of breast can-
cer are unlikely until we develop an understanding ofthe genetics and developmental biology of the normal
mammary gland. The breast is one of the most complex
genetic organs within the body. This is because DNA ex-
pression is under the control and influence of the hor-
monal milieu present in the circulation, which changes
as a function of age; and for premenopausal women as a
function of the menstrual cycle. We have taken advan-
tage of a unique research resource: The Susan G. Komen
for the Cure Tissue Bank at the IU Simon Cancer Center
(KTB), a biorepository of normal, healthy breast tissue,
to complete the first ever next-generation transcriptome
sequencing of epithelial compartment of 20 normal hu-
man breast specimens. This work has produced an initial
catalog of the differences in the expression of protein-
coding genes as a function of the phase of the menstrual
cycle. Gene expression in the breast epithelium was also
compared between women using HC and those not.
Gene expression increased in the luteal phase for the
majority of the differentially expressed genes. The prod-
ucts of these genes regulate the cell cycle, mitosis, DNA
licensing and replication, and the response to DNA
damage including checkpoints and repair. Their expres-
sion is likely to have been a consequence of paracrine ef-
fectors of progesterone including RANKL, WNT4 and
EREG. The breast epithelium of women using HC from
the perspective of gene expression is that of a premeno-
pausal woman during the luteal phase.
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